Table 1.
Patient Characteristics.
| Characteristic | Total, n(%)/median(range) |
|---|---|
| Age(years) | 55(36-76) |
| Primary site of disease | |
| Ovary | 107(90.7) |
| Paritoneum | 3(2.5) |
| Fallopian tube | 8(6.8) |
| FIGO Stage | |
| III | 100(84.7) |
| IV | 18(15.3) |
| Tumor Grade | |
| G1 | 4(3.4) |
| G2 | 11(9.3) |
| G3 | 98(83.1) |
| UnKnown | 5(4.2) |
| Histology | |
| Serous | 101(85.6) |
| Endometrioid | 3(2.5) |
| Clear cell | 6(5.1) |
| Mucinous | 1(0.9) |
| Others | 7(5.9) |
| Neoadjuvant chemotherapy | |
| TC/TP | 76(64.4) |
| PAF-C | 33(28.0) |
| Others | 9(7.6) |
| Cycles of neoadjuvant chemotherapy | |
| 1 | 42(35.6) |
| 2 | 50(42.4) |
| 3 | 23(19.5) |
| ≥4 | 3(2.5) |
| CA125U/ml presentation | 1814.5(56.6-56541.0) |
| CA125U/ml≤1800U/ml presentation | |
| Yes | 60(50.8) |
| No | 58(49.2) |
| CA125U/ml after the 1st NAC | 844.0(18.5-25000.0) |
| CA125U/ml≤850U/ml after the 1st NAC | |
| Yes | 57(48.3) |
| No | 54(45.8) |
| UnKnown | 7(5.9) |
| Reduction CA125U/ml after the 1st NAC(%) | 32.4(-324.9-98.9)** |
| Reduction CA125U/ml>30% after the 1st NAC | |
| Yes | 59(50.0) |
| No | 52(44.1) |
| UnKnown | 7(5.9) |
| CA125U/ml preoperatively | 205.9(9.3-10971.0) |
| CA125≤200U/ml preoperatively | |
| Yes | 58(49.2) |
| No | 60(50.8) |
| Reduction CA125U/ml presentation to preop (%) | 80.9(-152.0-99.5)** |
| Reduction CA125U/ml>80% presentation to preop | |
| Yes | 61(51.7) |
| No | 57(48.3) |
| Residual disease | |
| No visible residual | 37(31.4) |
| Residual disease≤2cm | 62(52.5) |
| Residual disease>2cm | 19(16.1) |
| Chemotherapeutic sensitive disease* | |
| Chemotherapeutic sensitive | 43(53.1) |
| Chemotherapeutic resistant or refractory | 38(46.9) |
*Some patients did not measure; **-342.9% and -152.0% means the CA125 levels increased by 342.9% and 152.0%.